IBD Biologics After COVID; Cutting Endoscopy Waste; New Humira Biosimilar OK'd

How soon after a COVID-19 infection is it OK to administer biologics for patients with inflammatory bowel disease (IBD)? (Clinical Gastroenterology and Hepatology)

Compared with second-dose side effects, gastrointestinal symptoms were slightly worse for IBD patients after a third dose of mRNA COVID vaccine, but otherwise post-shot symptoms were generally milder. (Inflammatory Bowel Diseases)

A targeted intervention to cut medical waste in endoscopy led to significant and sustained reductions in total and regulated medical waste while boosting recycling, European researchers reported in Gut.

Combining targeted drugs was safe and effective for patients with refractory or overlapping immune-mediated inflammatory diseases, a French study found. (Digestive and Liver Disease)

The FDA approved Hadlima, a citrate-free biosimilar to adalimumab (Humira) with indications in IBD, among other conditions, developers Samsung Bioepis and Organon announced.

Can anti-mitochondrial autoantibodies predict risk for primary biliary cholangitis? (Hepatology Communications)

Research from the Netherlands suggests patients with familial adenomatous polyposis who underwent proctocolectomy were more likely to develop ileal adenomas in the pouch rather than in the end ileostomy. (Gastrointestinal Endoscopy)

Young men with IBD since childhood experienced an increased risk of poorer bone quality in both the cortical and trabecular bone structures. (Inflammatory Bowel Diseases)

Comment